Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96SD1
UPID:
DCR1C_HUMAN
Alternative names:
DNA cross-link repair 1C protein; Protein A-SCID; SNM1 homolog C; SNM1-like protein
Alternative UPACC:
Q96SD1; D3DRT6; Q1HCL2; Q5JSR4; Q5JSR5; Q5JSR7; Q5JSR8; Q5JSR9; Q5JSS0; Q5JSS7; Q6PK14; Q8N101; Q8N132; Q8TBW9; Q9BVW9; Q9HAM4
Background:
Protein Artemis, known as DNA cross-link repair 1C protein, plays a crucial role in DNA non-homologous end joining (NHEJ), essential for double-strand break repair and V(D)J recombination. This process is vital for the assembly of immunoglobulins and T-cell receptor proteins, highlighting Artemis's pivotal role in immune system development and function.
Therapeutic significance:
Artemis's dysfunction is linked to severe combined immunodeficiency (SCID) variants, including autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive with sensitivity to ionizing radiation, SCID Athabaskan type, and Omenn syndrome. Understanding the role of Protein Artemis could open doors to potential therapeutic strategies for these life-threatening conditions.